



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/635		A1	(11) International Publication Number: WO 98/05683
			(43) International Publication Date: 12 February 1998 (12.02.98)
(21) International Application Number: PCT/CA97/00547		(74) Agent: ANDERSON, J., Wayne; National Research Council of Canada, Intellectual Property Services, Building M-58, EG-10, Montreal Road, Ottawa, Ontario K1A 0R6 (CA).	
(22) International Filing Date: 1 August 1997 (01.08.97)			
(30) Priority Data: 08/691,647 2 August 1996 (02.08.96) 60/040,560 14 March 1997 (14.03.97)		US	(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(71) Applicant (for all designated States except US): NATIONAL RESEARCH COUNCIL OF CANADA [CA/CA]; Intellectual Property Services Office, Building M-58, EG-12, Montreal Road, Ottawa, Ontario K1A 0R6 (CA).			
(72) Inventors; and (75) Inventors/Applicants (for US only): BARBIER, Jean-René [CA/CA]; 7 Beloeil Street, Gatineau, Quebec J8T 7G4 (CA). MORLEY, Paul [CA/CA]; 777 Southmore Drive West, Ottawa, Ontario K1V 6Z9 (CA). NEUGEBAUER, Witold [CA/CA]; 208 Provender Avenue, Ottawa, Ontario K1K 4N7 (CA). ROSS, Virginia [CA/CA]; 4611 Carrington Street, Gloucester, Ontario K1B 4R1 (CA). WHITFIELD, James [CA/CA]; 621 Manfield Avenue, Ottawa, Ontario K2A 2T3 (CA). WILLICK, Gordon, E. [CA/CA]; 1950 Kimball Court, Orleans, Ontario K1C 7C1 (CA).		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	

(54) Title: PARATHYROID HORMONE ANALOGUES FOR THE TREATMENT OF OSTEOPOROSIS

(57) Abstract

This invention describes analogues of human parathyroid hormone which have increased activities in bone restoration, and increased bioavailabilities. The peptides described are derivatives of hPTH-(1-31) which are cyclized for example, by formation of Lactams between either Glu²² and Lys²⁶ or Lys²⁶ and Asp³⁰. In addition, the natural Lys²⁷ may be substituted by either a Leu or other hydrophobic residues, such as Ile, norleucine, Met, Val, Ala, Trp, or Phe. Typically, these analogues have enhanced abilities to stimulate adenylyl cyclase in rat osteosarcoma cells, and show increased activities in bone restoration, using the ovariectomized rat model. The analogues also show enhanced activities and bioavailabilities, as demonstrated by their hypotensive effects in the rat. An assay which correlates hypotensive activity with osteogenic activity is also described.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

PARATHYROID HORMONE ANALOGUES FOR THE
TREATMENT OF OSTEOPOROSIS

5 Field of the Invention

This invention relates to analogues of human parathyroid hormone, which have been found to be effective in the treatment of osteoporosis.

10 Background of the Invention

Osteoporosis is a leading cause of disability in the elderly, particularly elderly women. It has recently been realized that human parathyroid hormone (hPTH) and certain analogues are stimulators of bone growth that are useful 15 in the treatment of osteoporosis. Osteoporosis is a progressive disease which results in the reduction of total bone mass and increased bone fragility. This often results in spontaneous fractures of load-bearing bones and the physical and mental deterioration characteristic of immobilizing injuries. Postmenopausal osteoporosis is caused by the disappearance of estrogens 20 which trigger a decade-long acceleration of bone turnover with an increased imbalance between resorption of old bone and formation of new bone. This results in thinning, increased porosity, and trabecular depletion of load-bearing bones. Osteoporosis is also associated with hyperthyroidism, hyperparathyroidism, Cushing's syndrome, and the use of certain steroid drugs. Remedies historically have involved increase in dietary calcium, 25 estrogen therapy, and increased doses of vitamin D, but mainly with agents such as antiresorptives that inhibit bone resorption by osteoclasts.

Parathyroid hormone (PTH) is produced by the parathyroid gland and is a major regulator of blood calcium levels. PTH is a polypeptide and 30 synthetic polypeptides may be prepared by the method disclosed by Erickson and Merrifield , The Proteins , Neurath et al., Eds., Academic Press, New York, 1976, page 257, and as modified by the method of Hodges et al (1988)

Peptide Research 1, 19 or by Atherton, E. And Sheppard, R.C. Solid Phase Peptide Synthesis, IRL Press, Oxford, 1989.

When serum calcium is reduced to below a normal level, the parathyroid gland releases PTH and the calcium level is increased by 5 resorption of bone calcium, by increased absorption of calcium from the intestine, and by increased renal reabsorption of calcium from nascent urine in the kidney tubules. Although continuously infused low levels of PTH can remove calcium from the bone, the same low doses, when intermittently injected can actually promote bone growth.

10 Tregeair, U.S. Patent 4,086,196, described human PTH analogues and claimed that the first 27 to 34 amino acids are the most effective in terms of the stimulation of adenylyl cyclase in an in vitro cell assay. Rosenblatt, U.S. patent 4,771,124, disclosed the property of hPTH analogues wherein Trp²³ is substituted by amino acids phenylalanine, leucine, norleucine, valine, 15 tyrosine, β-naphthylalanine, or α-naphthylalanine as a PTH antagonist. These modified hPTH analogues also have the 2 and 6 amino terminal acids removed, resulting in loss of most agonist activities when used to treat osteoporosis. These analogues were designed as inhibitors of PTH and PTH-related peptide. The analogues were claimed as possibly useful in the 20 treatment of hypercalcemia associated with some tumors.

Pang et al, WO93/06845, published April 15, 1993, described 25 analogues of hPTH which involve substitutions of Arg²⁵, Lys²⁶, Lys²⁷ with numerous amino acids, including alanine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine. These are claimed, with no supporting data from animal or human trials, to be effective in the treatment of osteoporosis with minimal effects on blood pressure and smooth muscle.

30 PTH operates through activation of two second messenger systems, G_s-protein activated adenylyl cyclase (AC) and G_q-protein activated phospholipase C_β. The latter results in a stimulation of membrane-bound

protein kinase Cs (PKC) activity. The PKC activity has been shown to require PTH residues 29 to 32 (Jouishomme et al (1994) *J. Bone Mineral Res.* **9**, (1179-1189). It has been established that the increase in bone growth, i.e. that effect which is useful in the treatment of osteoporosis, is coupled to the 5 ability of the peptide sequence to increase AC activity. The native PTH sequence has been shown to have all of these activities. The hPTH-(1-34) sequence is typically shown as (A):

10 Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His
Leu Asn Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu
Gln Asp Val His Asn Phe-OH

A

15

The following linear analogue, hPTH-(1-31)-NH₂, for which data is included in Table 1, below, has only AC-stimulating activity and has been shown to be fully active in the restoration of bone loss in the ovariectomized rat model 20 (Rixon, R. H. et al (1994) *J. Bone Miner. Res.* **9**, 1179-1189; Whitfield et al (1996), *Calcified Tissue Int.* **58**, 81-87; Willick et al, U.S. Patent No. 5,556,940 issued 17 September 1996):

25 Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His
Leu Asn Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu

Gln Asp Val-NH₂

B

30 The above molecule, B, may have a free carboxyl ending instead of the amide ending illustrated.

It is an object of the present invention to produce new PTH analogues with greater metabolic stability, increased bone restoration activity, increased AC activity, and minimal clinical side effects.

35

Brief Summary of the Invention

According to one aspect of the invention, human parathyroid hormone hPTH and pharmaceutically acceptable salts thereof are provided, having the amino acid sequence.

5

R-NH-R1-Val-Ser-Glu-Ile-Gln-Leu-R2-His-Asn-Leu-Gly-Lys-R3-R4-R5-R6-R7-Glu-Arg-Val-R8--Trp-Leu-R9--R10--R11-Leu-R12-Asp--Y

wherein,

10

R = hydrogen or any linear or branched chain alkyl, acyl or aryl group,

R1 = Ser, Ala or Aib,

R2 = Met, or a naturally occurring hydrophobic amino acid,

R3 = His or a water soluble amino acid,

15 R4 = Leu or a water soluble amino acid,

R5 = Asn or a water soluble amino acid,

R6 = Ser or a water soluble amino acid,

R7 = Met, or a naturally occurring hydrophobic amino acid,

R8 = Glu, Lys or Asp,

20 R9 = Cys, Glu or Orn,

R10 = Arg, Lys, Orn, Gln, Glu or Asp

R11 = a naturally occurring hydrophobic or polar amino acid,

R12 = Gln, Arg, Glu, Asp, Lys or Orn,

X = OH, NH₂, and

25 Y = X, Val-X, Val-His-X, Val-His-Asn-X, Val-His-Asn-Phe-X, Val-His-Asn-Phe-Val-X, Val-His-Asn-Phe-Val-Ala-X and Val-His-Asn-Phe-Val-Ala-Leu-X, cyclized as between one or two amino acid pairs 22 and 26, 26 and 30, 27 and 30, and 25 and 29 when R3 and R6 are Lys, Orn, Glu or Asp, excluding cyclo(Lys²⁶-Asp³⁰)[Leu²⁷]-hPTH-(1-34)-NH₂, cyclo(Lys²⁷-Asp³⁰)-h-PTH-(1-34)-NH₂ and cyclo(Lys²⁶-Asp³⁰)-[Leu²⁷]-hPTH-(1-34)-OH.

Examples of the salts include salts of inorganic acids, salts of organic acids such as formic acid, acetic acid, tartaric acid and citric acid, salts of inorganic bases such as sodium and ammonium and salts of organic bases 5 such as triethylamine, ethylamine and methylamine.

According to another feature of the present invention, cyclisation is effected by the formation of lactams, involving the coupling of the side-chains of the selected amino acid pairs such as between natural residues 22 and 26, or 26 and 30. Other types of cyclisations, such as the formation of a disulfide 10 bridge e.g. between Cys containing analogues Cys²²-Cys²⁶ and Cys²⁶-Cys³⁰ are also contemplated.

Substitutions of various amino acids have also been found to be effective. Lys²⁷ may be replaced by a Leu or by various other naturally occurring hydrophobic or polar residues. Another factor is how well the 15 residue fits to the receptor. Ala is not as hydrophobic as Leu. Lys and Tyr are generally considered to be polar, but nonetheless have hydrophobic interactions with the receptor. Lys, for example, can fold so that the hydrophobic part interacts with other hydrophobic residues in the receptor, and the NH₂ is exposed to solvent. Such substitutions include ornithine, 20 citrulline, α -aminobutyric acid, alanine, norleucine, isoleucine and tyrosine, or any linear or branched α -amino aliphatic acid, having 2-10 carbons in the side chain, any such analogue having a polar or charged group at the terminus of the aliphatic chain. Examples of polar or charged groups include; amino, carboxyl, acetamido, guanido and ureido. Although it appears that Leu²⁷ is 25 the best substitution, it also appears that many other pos27 substitutions retain nearly full activity and could also have desired properties, such as increased proteolytic stability or water solubility, Ile, norleucine, Met, and ornithine are expected to be the most active.

This substitution results in a stabilization of an α -helix in the receptor- 30 binding region of the hormone. This has been confirmed by examination of the circular dichroism spectrum of the lactam analogues, as compared to the

circular dichroism spectrum of the linear molecule, [Leu²⁷]-hPTH-(1-31)-NH₂. Circular dichroism spectra are highly sensitive to the presence of α -helical secondary structure, and the technique has been used to demonstrate the presence of α -helix in hPTH fragments (Neugebauer et al (1991) 5 *Biochemistry* **31**, 2056-2063). Furthermore, the stabilization of α -helix on formation of the above mentioned lactams in hPTH-(20-34)-NH₂ has been shown (Neugebauer et al (1994) *Int. J. Protein Peptide Res.* **43**, 555-562). There is a potential amphiphilic α -helix between residues 21 and 31 of hPTH- 10 (1-31)-NH₂, and data has been presented showing that the hydrophobic face of this helix interacts with the PTH receptor (Neugebauer, W.(1995) et al *Biochemistry* **34**, 8835-8842; Gardella, T. J. et al (1993), *Endocrinology* **132**, 2024-2030).

It has been found that the most effective cyclisation involves the formation of a lactam, for example, between either residues Glu²² and Lys²⁶, 15 or Lys²⁶ and Asp³⁰. Other cyclisations are also possible such as between Lys²⁷ and Asp³⁰, although this lactam has been found to exhibit some destabilizing effect on the α -helix.

More specifically, receptor-binding studies of PTH fragments have indicated a principal binding region within residues 14-34.¹ We have 20 suggested that the residues 17-29 α -helix binds as such to the PTH receptor, and that the amphiphilic portion of this α -helix binds with its hydrophobic face to the receptor.² This model is consistent with the results of a study of receptor binding-region analogues.³

NMR studies have shown that even a model peptide found to be 25 highly helical by CD also populates many non-helical conformations. Thus, the structure of a receptor-bound peptide hormone, such as PTH, can not be inferred reliably from its free structure in solution. Constrained analogues of peptide hormones have been used to limit the number of conformational states available to the peptide⁸. Examination of the sequence of hPTH

reveals 3 possible salt bridges within residues 17-29 which could either stabilize or destabilize α -helix. These are between Glu²² and Lys²⁶, and Lys²⁶ and Asp³⁰, both of which are expected to stabilize an α -helix, and between Lys²⁷ and Asp³⁰, which is expected to destabilize an α -helix.⁴ Lactam formation between these residue pairs would restrict the conformations available to hPTH in this helical region. Furthermore, two of these lactams, Glu²²-Lys²⁶ and Lys²⁶-Asp³⁰ which are expected to stabilize α -helical structure are located on the polar face of the amphiphilic portion of the α -helix. The third one, Lys²⁷-Asp³⁰, is expected to at least partially destabilize α -helix and involves a residue, Lys²⁷, which is on the hydrophobic face of the amphiphilic helix. Cyclisation as between positions 25 and 29 can also occur if Lys or Orn replaces Arg in position 25, and if Gln²⁹ is replaced with Glu or Asp.

The substitution of Leu for the Lys²⁷ results in a more hydrophobic residue on the hydrophobic face of the amphiphilic helix. This resulted in increased adenylyl cyclase stimulating activity in the ROS cell line. It will be appreciated by those skilled in the art that other such substitutions discussed above would likely result in analogues with the same or increased activities.

The combined effect of substitution and either lactam formation is expected to stabilize the α -helix and increase bioactivity, and to protect this region of the molecule from proteolytic degradation. The presence of the amide at the C-terminus is preferred in the sense that it is further expected to protect the peptide against exoproteolytic degradation, although some peptidases can hydrolyze them. (Leslie, F.M. and Goldstein, A. (1982) *Neuropeptides* 2, 185-196).

It has also been found that other amino acid substitutions can usefully be made. Specifically, we have replaced the oxidation sensitive Met residue at positions 8,18 with a naturally occurring hydrophobic residue, Nle, as per Japanese Patent publication 61-24598. It is also to be expected that other such hydrophobic residues like Leu, Ile, Val, Phe and Trp would also be useful, as per USP 5,393,869 to Nakagawa et al.

Reverse lactams are also contemplated. For example, we have shown the effectiveness of a Lys²²-Glu²⁶ switch. It is therefore to be expected that similar switches could be usefully be made as between the 26-30 and 27-30 lactams.

5 Another substitution at the preferred 22-26 lactam site, in addition to the aforementioned Cys-Cys, ie Asp²²-Orn²⁶ has been done to illustrate that different cyclisation/ring sizes can usefully be made.

In USP 5,393,869 Nakagawa et al and USP 5,434,246, Fukuda et al some substituted hPTH analogues were reported to have substantial AC 10 activity and might have enhanced stabilities to proteolytic attack, specifically,

1. Ser-1 to Aib (α -aminoisobutyric acid)
2. Lys-27 to Gln (reported to have 2.5 x AC activity)
3. Residues 14, 15, 16, 17 to Lys, in whole or in part 9reported to greatly increase activity - up to 8X. This may be due to increase in water 15 solubility. *In vivo*, these are expected to be more labile to trypsin-like enzymes). They claim this tetrapeptide (residues 14-17, incl.) such that there is at least one water soluble amino acid. For example His-14 or Lys-14; Leu-15, Lys-15 or Arg-15; Asn-16, Orn-16, Hci (homocitrulline)-16, Asp-16, Arg-16, Lys-16, DLys-16, Ser-16 or Gly-16; and 17-Ser, 17-Lys, 17-Asp or 17-Arg.
- 20 Could also include Glu, for example.

4. Arg 25 to His to minimize protease attack. Since our lactams, particularly with Leu or another hydrophobic amino acid at position-27, can become somewhat insoluble and also difficult to dissolve, it would be expected that the same substitutions would be useful in our lactams.

25 It will also be appreciated by those skilled in the art that although the 1-31 h-PTH cyclics may be preferred, it is to be expected from the data presented herein that cyclic fragments in the range of 1-30 to 1-37 will also be effective. In particular, there is no evidence in the literature that the presence of additional amino acids up to 37 affect the biological properties of the 30 hormone, particularly given the confirmatory 1-34 data included herein.

The lactams according to the invention may be prepared by known procedures described below, and may be used for stimulating bone growth,

for restoring bone, and for the promotion of bone healing in various circumstances, such as in the treatment of osteoporosis and normal fractures.

Brief Description of the Drawings

5

Fig. 1 shows the structure of natural human PTH, residues 1-31 (SEQ ID NO: 1);

10 Fig. 2 shows the structure of [Leu²⁷]cyclo(Glu²²-Lys²⁶)-hPTH-(1-31)-NH₂ (SEQ ID NO: 3);

Fig. 3 shows the structure of [Leu²⁷]cyclo(Lys²⁶-Asp³⁰)-hPTH-(1-31)-NH₂ (SEQ ID NO: 4);

15 Fig. 4 shows the activities of the analogues according to the invention in adenylyl cyclase stimulation of ROS 17/2 cells;

Fig. 5 shows representative histological sections of bones prepared at the end of 8 weeks after OVX, illustrating the different abilities of 20 hPTH-(1-31)NH₂ and its lactam derivatives to prevent bone loss and to stimulate bone growth in ovariectomized (OVX) Sprague-Dawley rats;

Fig. 6 shows the trabecular bone volume of control animals and hPTH analogue treated animals for rats initially severely depleted of bone. 25 Treatment of the animals began 9 weeks after OVX. [Leu²⁷]cyclo[Glu²²-Lys²⁶]hPTH-(1-31)-NH₂ was the most effective of the fragments, restoring the bones to the values in normal control rats; and

30 Fig. 7 shows trabecular thicknesses of rat femurs for normal, ovariectomized (OVX), sham, and animals treated with hPTH-(1-31)-NH₂, [Leu²⁷]cyclo(Glu²²-Lys²⁶)-hPTH-(1-31)-NH₂, and [Leu²⁷]cyclo(Lys²⁶-Asp³⁰)-hPTH-(1-31)-NH₂;

Fig. 8 shows the maximum drop in blood pressure and time to maximum drop in blood pressure on addition of 0.8 nmol/100g dose of hPTH-(1-31)-NH₂, [Leu²⁷]cyclo(Glu²²-Lys²⁶)hPTH-(1-31)-NH₂, or [Leu²⁷]cyclo(Lys²⁶-Asp³⁰)hPTH-(1-31)-NH₂. Peptides were administered either subcutaneously (open bar) or 5 intravenously (hatched bar).

Fig. 9 shows the structure of [Leu²⁷]-hPTH-(1-31)-NH₂(SEQ ID NO:5).

Fig. 10 shows the structure of cyclo (Lys²⁷-Asp³⁰)-hPTH-(1-31)-NH₂(SEQ ID 10 NO:6)

Fig. 11 shows the structure of [Leu²⁷] cyclo (Glu²²-Lys²⁶)-hPTH-(1-30)-NH₂ (SEQ ID NO:7)

15 Fig. 12 shows the adenyl cyclase stimulating activites of various analogs according to the invention.

Fig. 13 shows hypotensive actions of hPTH(1-31)NH₂ and hPTH(1-30)NH₂ and their cyclic analogues.

20 Fig. 14 is a graph illustrating the effect on bone growth of different dosages of linear hPTH(1-31)-NH₂.

Fig. 15 shows the structure of [Leu²⁷] cyclo (Glu²²-Lys²⁶)-hPTH-(1-31)-OH 25 (Seq. ID No: 8)

Fig. 16 shows the structure of [Leu²⁷] cyclo (Glu²²-Lys²⁶)-hPTH-(1-34)-NH₂ (Seq. ID No: 9)

30 Fig. 17 shows the structure of [Leu²⁷] cyclo (Glu²²-Lys²⁶)-hPTH-(1-34)-OH (Seq. ID No: 10)

Fig. 18 shows the structure of [Ala²⁷] cyclo (Glu²²-Lys²⁶)-hPTH-(1-31)-NH₂
(Seq. ID No: 11)

5 Fig. 19 shows the structure of [Nle²⁷] cyclo (Glu²²-Lys²⁶)-hPTH-(1-31)-NH₂
(Seq. ID No: 12)

Fig. 20 shows the structure of [Nle^{8,18}; Leu²⁷] cyclo (Glu²²-Lys²⁶)-hPTH-(1-31)-NH₂

10 (Seq. ID No: 13)

Fig. 21 shows the structure of cyclo (Glu²²-Lys²⁶)-hPTH-(1-31)-NH₂
(Seq. ID No: 14)

15 Fig. 22 shows the structure of [Ile²⁷] cyclo (Glu²²-Lys²⁶)-hPTH-(1-31)-NH₂
(Seq. ID No: 15)

Fig. 23 shows the structure of [Tyr²⁷] cyclo (Glu²²-Lys²⁶)-hPTH-(1-31)-NH₂
(Seq. ID No: 16)

20 Fig. 24 shows the structure of α -acetyl-[Leu²⁷] cyclo (Glu²²-Lys²⁶)-hPTH-(1-31)-NH₂
(Seq. ID No: 17)

25 Fig. 25 shows the structure of [Leu²⁷] cyclo (Lys²²-Glu²⁶)-hPTH-(1-31)-NH₂
(Seq. ID No: 18)

Fig. 26 shows the structure of [Leu²⁷] cyclo (Asp²²-Orn²⁶)-hPTH-(1-31)-NH₂
(Seq. ID No: 19)

Fig. 27 shows the structure of [Cys²²; Cys²⁶ ; Leu²⁷] cyclo (Cys²²-Cys²⁶)-hPTH-(1-31)-NH₂

(Seq. ID No: 20)

5 Fig. 28 shows the structure of [Cys²⁶ ; Cys³⁰ ; Leu²⁷] cyclo (Cys²⁶-Cys³⁰)-hPTH-(1-31)-NH₂

(Seq. ID No: 21)

10 Preparation of Hormone Analogues

The technique of solid phase peptide synthesis developed by R.B. Merrifield ("Solid-Phase Peptide Synthesis", Advances in Enzymology 32, 221-296, 1969), incorporated herein by reference, is widely and successfully used for the synthesis of polypeptides such as parathyroid hormone. The strategy is 15 based on having the carboxyl-terminus amino acid of the peptide attached to a solid support. Successive amino acids are then added in high yield. The N-terminal α -amino group is protected in such a way that this protecting group can be removed without removal of the peptide from the solid support. The chemistry used here involves a modification of the original Merrifield method, 20 referred to as the Fmoc approach. The Fmoc (fluorenylmethoxycarbonyl) group can be removed by mild alkaline conditions, which leaves the alkali stable side-chain protecting groups and the link to the support untouched. This technique is described by E. Atherton and R.C. Sheppard, "Solid Phase Peptide Synthesis: a Practical Approach", IRL Press, New York, N.Y., 25 incorporated herein by reference.

Example 15 Synthesis and Purification of Linear hPTH-(1-31)-amide Analogues

The α -amino groups of the amino acids were protected by 9-fluorenylmethoxycarbonyl (Fmoc) during coupling. Couplings were performed with a mixture of hydroxybenzotriazole (HOBt), 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU), and diisopropylethylamine (DIPEA). A 4-fold excess of activated amino acids was used with double coupling on addition of the Asn, Gln, His, Val, and Ile residues. The coupling times for Arg and Gly additions were increased from 30 to 60 minutes. Coupling of the first residue (Val³¹) to the support (Tentagel* R, Rapp Polymere, Tubingen, Germany) was performed manually. All other steps were performed on a PerSeptive Biosystems* Model 9050 Plus automated peptide synthesizer. Side chain protections were as follows: Arg (2,2,5,7,8-pentamethylchroman-6-sulfonyl); Glu, Asp, and Ser (*t*-butyl); His, Gln, and Asn (trityl); Trp (*t*-butyloxycarbonyl).

20 After Fmoc removal from the N-terminal Ser, the peptide resin was washed with DCM, then cleaved from the resin by shaking with 7.5 ml of reagent K (6.19 ml TFA, 0.38 ml each of water, 90% phenol/water, and thioanisole, and 0.19 ml of 1,2-ethanedithiol) for 4 hr at 20 °C. The cleaved peptide mixture was removed by filtration, and precipitated by addition to *t*-butyl-methylether. The precipitate was collected by centrifugation, washed 2x with *t*-butyl-methylether, then dried by vacuum centrifugation.

25 The crude product was dissolved in 14 ml of 15% acetonitrile/water, 0.1% TFA and chromatographed on a Vydac* C₁₈-column (10 μ , 1 x 25 cm). The product was eluted with a 1%/min. gradient of acetonitrile (14-40%) in 30 0.1% TFA in water. The purity of the final product was estimated by analytical HPLC on a Vydac* C₁₈ column (10 μ , 0.4 x 25 cm), and by molecular mass

assay on an electrospray mass spectrometer (VG Quattro). The data for hPTH-(1-31)-NH₂ so formed, is given in Table 1 below.

Example 2

5

Synthesis and Purification of Cyclic Analogues

[Leu²⁷]cyclo(Glu²²-Lys²⁶)-hPTH-(1-31)-NH₂. This peptide was synthesized as described for Example 1, with Lys-Alloc and Glu-OAll 10 substituted at position 26 and 22, respectively. After the addition of Fmoc-Ser¹⁷, the peptide-resin was removed from the column to a reaction vial (Minivial*, Applied Science), suspended in 1.7 ml of a solution of tetrakis(triphenylphosphine)palladium(0) (0.24 mmol), 5% acetic acid and 2.5% N-methylmorpholine (NMM) in dichloromethane (DCM) under argon, 15 then shaken at 20°C for 6 hr to remove the allyl and alloc protecting groups (Solé, N.A. et al (1993) In *Peptides: Chemistry, Structure, and Biology*, Smith, J. And Hodges, R. (Eds), ESCOM pp. 93-94), incorporated herein by reference. The peptide resin was then washed with 0.5 % diethyldithiocarbamate (DEDT), 0.5 % NMM in DMF (50 ml), followed by DMF 20 (50 ml) and DCM (50 ml). The peptide (0.06 mmol) was cyclized by shaking with 0.06 mmol of 1-hydroxy-7-azabenzotriazole (HOAt) / 0.12 mmol NMM in 2 ml DMF for 14 h at 20 °C (Carpino, L.A. (1993) *J. Am. Chem. Soc.* 115, 4397-4398). The peptide-resin was filtered, then washed once with DMF, repacked into the column, and washed with DMF until bubbles were removed 25 from the suspension. The remaining synthesis was carried out as with Example 1 except that the N-terminal Fmoc group was not removed. The Fmoc-peptide was cleaved from the resin with reagent K as described above. The HPLC was carried out as in Example 1, with the Fmoc group removed prior to the final HPLC.

30 Analogue [Leu²⁷]cyclo(Lys²⁶-Asp³⁰)-hPTH-(1-31)-NH₂ was prepared in an analogous manner.

Example 3Adenylyl Cyclase Assays

5 The ability of the hPTH analogues to bind to receptors and activate the adenylyl cyclase coupled signalling mechanism was determined on a differentiation-competent osteoblast-like ROS 17/2 rat osteosarcoma (ROS) cell line. This activity is known to be tightly coupled to the ability of the analogue to restore bone mass in the ovariectomized rat. Adenylyl cyclase-stimulating activity was estimated by prelabelling the cellular ATP pool with $[^3\text{H}]\text{-adenine}$ and then measuring the amount of $[^3\text{H}]\text{-cyclic AMP}$ produced from the $[^3\text{H}]\text{-ATP}$ during the first 10 min of exposure to a particular analogue. This was based on the procedure described by Whitfield et al, *J. Cellular Physiology* 150, 299-303, 1992, incorporated herein by reference.

10 15 The adenylyl cyclase results are expressed in Table 2 below as the concentration necessary to express a half-maximal increase in the AC activity. The data is also displayed in Fig. 4. In Fig. 4, the closed circles show the adenylyl cyclase-stimulating activity of hPTH-(1-31)-NH₂, and the activities of $[\text{Leu}^{27}]\text{cyclo}(\text{Glu}^{22}\text{-Lys}^{26})\text{-hPTH-(1-31)-NH}_2$ and $[\text{Leu}^{27}]\text{cyclo}(\text{Lys}^{26}\text{-Asp}^{30})\text{-hPTH-(1-31)-NH}_2$ are shown by open and closed triangles, respectively.

20

Example 4Determination of Anabolic Activities of hPTH Analogues with Ovariectomized5 Rat Model

Dosages:

Doses were based upon dose-response data on hPTH(1-31)-NH₂. The bone-building potency of hPTH-(1-31)NH₂ was tested using several doses (0.8, 10 0.6, 0.4, and 0.2 nmole/100 g of body weight) and a *regenerative* or treatment-assessing, rather than preventative, model.¹¹ Ovariectomized 3-months-old rats, were left for 9 weeks to let the mostly non-lamellar femoral trabecular bone be severely depleted before starting the 6 weeks of daily injections. By the end of the 9th week they had lost about 75% of their 15 femoral trabecular bone mass. Figure 14 shows the dose-dependent increase in the mean trabecular thicknesses caused by lamellar deposition that had been produced by the 36 injections of 4 different doses of the fragment. The fragment could also stimulate trabecular bone growth in much older rats. Thus, 36 injections of the mid-range dose of 0.6 nmole/100g of 20 body weight of hPTH-(1-31)NH₂ were able to significantly increase the mean trabecular thickness above the normal starting value in the predepleted (9 weeks after OVX femoral trabecular bone of 1-year-old rats, and they did so as effectively as hPTH-(1-84). Accordingly, the dosage of 0.6 nmole/100g of body weight was used in further tests.

25

A full description of the protocol is given in Rixon et al, *J. Bone & Mineral Research* 9, 1179-1189, 1994 and Whitfield et al *Calcif. Tissue Int.* 58, 81-87, 1996 incorporated herein by reference. Normal, Sham-OVX (ovariectomized), and OVX Sprague-Dawley rats (3 months-old ;255-260g) 30 were purchased from Charles River Laboratories (St.Constant, QC). The rats were randomized into groups of 8 animals which received Purina rat chow and water ad libitum. There were no unscheduled deaths. The animals

received 6, once-daily subcutaneous injections / week starting at the end of the second week after OVX, and ending at the end of the 8th week after OVX (i.e., 36 injections). Eight Sham-OVX and 8 OVX controls rats received 36 injections of vehicle (0.15 M NaCl containing 0.001N HCl) while 8 OVX rats 5 received 0.6 nmole of fragment in vehicle/ 100 g of body weight). At the end of the 8th week after OVX, femurs were removed isolated, cleaned, and cut in half at mid-diaphysis and the proximal half was discarded. After removing the epiphysis, each half-femur was split lengthwise into two parts and the bone marrow was flushed out.

10 The bone-building potencies of the fragments were assessed from the changes in the mean thicknesses (area/perimeter) of the trabeculae in the distal half-femurs from the variously treated animals. To measure mean trabecular thickness , the two demineralized half-femurs from each rat were dehydrated and embedded in paraffin. Longitudinal, 10- μ m sections from the 15 middle plane of each bone were cut and then stained with Sanderson's rapid bone stain (Surgipath Medical Industries, Inc., Winnipeg, MB, Canada). The mean trabecular thickness was measured using a M4 imaging system and bone morphometric software from Imaging Research Inc., (St. Catherines, ON, Canada).

20 Representative histological sections of bones prepared at the end of 8 weeks after OVX are shown in Figure 5. The results are further presented in the form of a bar graph in Fig. 7. The bars show the values for trabecular thickness of the normal, ovariectomized (OVX), sham, hPTH-(1-31)-NH₂, [Leu²⁷]cyclo(Glu²²-Lys²⁶)-hPTH-(1-31)-NH₂, and [Leu²⁷]cyclo(Lys²⁶-Asp³⁰)- 25 hPTH-(1-31)-NH₂. [Leu²⁷]cyclo(Glu²²-Lys²⁶)-hPTH-(1-31)-NH₂ shows an especially superior activity compared to the linear analogue, hPTH-(1-31)-NH₂. This linear analogue has been shown to be fully active in bone restoration, but uses only one cellular signalling (the AC-activated) pathway. Thus, these cyclic analogues, like their linear analogue, are expected to have 30 fewer undesired clinical side-effects than their longer counterparts, such as

hPTH-(1-34) or hPTH-(1-84), which activate both cellular signalling mechanisms.

Example 5

5

Bone Restoration by hPTH Analogues of Rats with Severely Depleted Trabecular Bone.

In this second example of bone restoration, the abilities of the lactam fragments to restore severely depleted trabecular bone are compared. In this experiment, the 6-week program of once-daily injections of 0.6 nmole of peptide/100g of body weight of young sexually mature rats was delayed until the end of the 9th week after OVX. At this time, 75% of their trabecular bone had been lost. As can be seen in Fig. 6, [Leu²⁷]cyclo[Glu²²-Lys²⁶]-hPTH-(1-31)NH₂ was the most effective of the fragments. It restored the trabecular bone volume to the values in normal control rats.

Example 6

20

Hypotensive Effects of hPTH Analogues

Female Sprague-Dawley rats (weighing over 290 g) were anaesthetized with intraperitoneally injected sodium pentobarbital (65 mg/kg body weight). Rectal temperature was monitored with a YSI402 thermistor (Yellow Springs Instrument Co., Inc. Yellow Springs, OH) and maintained between 36.0 and 38.5 °C throughout the experiment. Ear pinna temperature was also monitored using a YSI banjo thermistor. The tail artery was exposed and cannulated with a Jelco 25-gIV catheter (Johnson and Johnson Medical Inc., Arlington, TX) and connected to a Statham pressure transducer, the signals from which were recorded digitally with a Biopac Systems MP100 Monitor (Harvard Instruments, Saint Laurent, QC, Canada). For intravenous

injection of PTH or one of its fragments, a femoral vein was also exposed. After surgery, the rat was allowed to stabilize for 8 min after which PTH or one of its fragments (dissolved in acidified saline containing 0.001 N HCl) was injected into the femoral vein or under the skin of the abdomen. Data were 5 collected for 12 min after intravenous injection or for 22 min after subcutaneous injection. Fig. 8 shows the maximum drop in blood pressure and time to maximum drop on addition of 0.8 nmol/100g dose of $[\text{Leu}^{27}]\text{cyclo}(\text{Glu}^{22}\text{-Lys}^{26})\text{hPTH-(1-31)-NH}_2$ or $[\text{Leu}^{27}]\text{cyclo}(\text{Lys}^{26}\text{-Asp}^{30})\text{hPTH-(1-31)-NH}_2$ for administration by either subcutaneous (open bar) or 10 intravenous (hatched bar) route. The $[\text{Leu}^{27}]\text{cyclo}(\text{Glu}^{22}\text{-Lys}^{26})\text{hPTH-(1-31)-NH}_2$ analogue shows increased bioavailability, as compared to $[\text{Leu}^{27}]\text{cyclo}(\text{Lys}^{26}\text{-Asp}^{30})\text{hPTH-(1-31)-NH}_2$. This is indicated by the much shorter time needed to drop to the minimum bp after subcutaneous injection. Both cyclic analogues show enhanced hypotensive effects when injected 15 subcutaneously, when compared to hPTH-(1-31)-NH₂. Thus, each cyclic lactam analogue, when injected subcutaneously, is expected to have more desirable properties than the linear counterpart. These include greater bioavailabilities, resulting from enhanced resistance to proteases and/or increased ability to be transported from lipidic environments. The latter could 20 be due to the stabilization of the amphiphilic helix near the C-terminus of the hormone.

Further results:

For the purpose of these results, the peptides are identified as follows.

25 hPTH-(1-31)-NH₂ (1); $[\text{Leu}^{27}]\text{-hPTH-(1-31)-NH}_2$ (2) (Fig. 9); $[\text{Leu}^{27}]\text{cyclo}(\text{Glu}^{22}\text{-Lys}^{26})\text{-hPTH-(1-31)-NH}_2$ (3) (Fig. 2); $[\text{Leu}^{27}]\text{cyclo}(\text{Lys}^{26}\text{-Asp}^{30})\text{-hPTH-(1-31)-NH}_2$ (4); $\text{cyclo}(\text{Lys}^{27}\text{-Asp}^{30})\text{-hPTH-(1-31)-NH}_2$ (5) (Fig. 10); hPTH-(1-30)-NH₂ (6); $[\text{Leu}^{27}]\text{hPTH-(1-30)-NH}_2$ (7); $[\text{Leu}^{27}]\text{cyclo}(\text{Glu}^{22}\text{-Lys}^{26})\text{-hPTH-(1-30)-NH}_2$ (8).

Adenylyl Cyclase Activities. We previously reported that [Leu²⁷]-hPTH-(1-34)-NH₂ is more active in stimulating AC activity in the ROS cell line than hPTH-(1-34)-NH₂.⁵ We have also found that peptide 2 (EC₅₀, 11.5 ± 5.2 nM) is more active than the native sequence 1, (EC₅₀, 19.9 ± 3.9 nM) (Fig. 12).

5 Shown are peptides 1 (•); 2 (□); 3 (Δ) 4 (▲) 5 (○). Lactam formation between Glu²² and Lys²⁶ (3) induced a still greater AC-stimulating activity, with EC₅₀ values of 3.3 ± 0.3 nM (Fig. 12). Thus, the net effect of this cyclization and replacement of Lys²⁷ with Leu is about a 6-fold increase in activity. In contrast, lactam formation between either Lys²⁶ and Asp³⁰ (4) or Lys²⁷ and

10 11 Asp³⁰ (5) resulted in a lessening of adenylyl cyclase stimulation, with respect to their parent linear sequences. Thus, the 26-30 lactam (4) has slightly less activity than its linear form, with an EC₅₀ of 17.0 ± 3.3 nM vs 11.5 ± 5.2 nM for 2. The 27-30 lactam (5) more markedly reduces the activity of the parent linear peptide, having an EC₅₀ of 40.3 ± 4.4 nM as compared to 19 ± 3.9 nM for

15 11.

We have previously reported that hPTH-(1-30)-NH₂ (6) has an AC-stimulating activity (EC₅₀, 20 nM), close to that of analogue 1. We have now found that [Leu²⁷]-hPTH-(1-30)-NH₂ (7) and cyclo(Glu²²-Lys²⁶)-hPTH-(1-30)-NH₂ (8) (Fig. 11) have similar AC-stimulating activities to peptide 6.

20

Hypotensive Effects:

Figure 13 shows the hypotensive action of linear (6 and 7) and cyclic lactam analogues (3 and 8). Shown are the maximum drops in blood pressure (upper) obtained on injecting the rat with 0.8 nmol/100 g of body weight of the

analogue and the time taken to attain the maximum drop in blood pressure (lower). The analogues (left to right, peptides **8, 7, 6, 3**) were injected either intravenously (shaded bar) or subcutaneously (open bar). Removal of Val³¹ resulted in all of analogues **6, 7, and 8** having significantly (p<0.05) reduced 5 rates of transport of the subcutaneously injected peptides to the vascular system (Fig. 13). The actual total blood pressure drops of peptides **6** and **8** were, nonetheless, not significantly different (p>0.05) from those of the other analogues, whether subcutaneously or intravenously administered, with the exception of peptide **5**.

10

ASSAY CORRELATING HYPOTENSIVE EFFECT WITH OSTEOGENIC ACTIVITY

As described in Example 6 and illustrated in Figure 8, a fast 15 hypotensive effect observed following subcutaneous injection of hPTH analogs correlates with osteogenic activity. Accordingly, the assay is useful for screening candidate hPTH analogs for osteogenic effect and to eliminate non-hypotensive constructs, without having to sacrifice laboratory test animals.

By way of background, we have used a unique set of osteogenic and 20 non-osteogenic AC-, AC/PLC-, or PLC-activating PTH fragments to definitively prove that it is only AC stimulation that reduces blood pressure and to compare the hypotensive actions of these fragments when they are injected subcutaneously or intravenously into female rats. We have shown that the hypotensive response is triggered only by AC- or AC/PLC-stimulating 25 fragments and that it is the relatively small hypotensive response to subcutaneous injection, and not the much larger response to intravenous injection, that correlates with the osteogenic activities of hPTH-(1-31)NH₂, hPTH-(1-34), and hPTH-(1-84) in OVX-rats, but not to hPTH-(1-30)NH₂,

which stimulates AC and reduces blood pressure, but does not stimulate bone formation.

Specifically, hPTH-(1-84), and its hPTH-(1-34), hPTH-(1-31)NH₂, and hPTH-(1-30)NH₂ fragments reduced the tail artery pressure in anesthetized 5 female Sprague-Dawley rats by 42.4-67.1% within about 1 minute after injection into a femoral vein, but reduced the pressure by only 8.5-36.2% 2-19 minutes after subcutaneous injection. hPTH-(1-84) and hPTH-(1-34) stimulate both adenylyl cyclase and phospholipase-C in their target cells, but the hypotensive action must have been stimulated specifically by adenylyl 10 cyclase activation, because hPTH-(1-30)NH₂ and hPTH-(1-31)NH₂, which can only stimulate adenylyl cyclase, were potently hypotensive when injected intravenously whereas hPTH-(7-84), which can only stimulate phospholipase-C, was not significantly hypotensive when injected intravenously. Since 15 PTH's osteogenic action is also mediated by adenylyl cyclase stimulation, it was expected that the hypotensive response might be used to screen new PTH constructs for possible osteogenicity. Indeed, the osteogenic activities of subcutaneously injected hPTH-(1-31)NH₂, hPTH-(1-34), and hPTH-(1-84) correlated closely to their hypotensive activities, with hPTH-(1-34) being much 20 more hypotensive and significantly more the other two molecules. hPTH-(1-31)NH₂ and hPTH-(1-84) were equally osteogenic and hypotensive. However, this correlation broke down with hPTH-(1-30)NH₂ which stimulates 25 AC almost as strongly as hPTH-(1-31)-NH₂ and hPTH-(1-34) and reduces blood pressure as much as hPTH-(1-31)-NH₂ but does not stimulate bone formation. Nevertheless, the ability to significantly reduce arterial pressure is a common property of osteogenic PTH and PTH fragments and is thus a rapidly determinable preliminary indicator of *in vivo* bioactivity of PTH fragments.

More specifically, both hPTH-(1-34) and hPTH-(1-31)-NH₂ were maximally hypotensive at 0.8 nmole/100g of body weight.

30 This hypotensive response was accompanied by a transient (20-30 minute) reddening of the rats' ears and paws, which can be considered as a useful visual qualitative marker.

This hypotensive response was accompanied by a transient (20-30 minute) reddening of the rats' ears and paws, which can be considered as a useful visual qualitative marker.

Though AC- or AC/PLC-stimulating fragments were potently 5 hypotensive when injected intravenously, an intravenous injection of 0.8 nmol/100 g of body weight of hPTH-(7-84), which can only stimulate PLC, very slowly (9.8 ± 2.0 minutes) and only very slightly, reduced the tail artery pressure by 3.28 ± 1.0 mm Hg compared with the prompt (0.9 ± 0.08 minutes) 43.2 ± 5.8 mm Hg reduction caused by the AC/PLC-stimulating hPTH-(1-84) 10 or the equally prompt 51.6 ± 3.3 mm Hg fall caused by the AC stimulating hPTH-(1-31)NH₂.

One subcutaneous injection of an AC- or AC/PLC stimulating fragment caused a much slower and smaller reduction in the tail artery pressure than an intravenous injection of the same dose. For example. 0.8 nmol/100 g of 15 body weight of hPTH-(1-34) reduced the pressure by only 27.9 ± 3.6 mm Hg when injected subcutaneously as compared with 50.9 ± 5.6 mm Hg when injected intravenously. The same dose of hPTH-(1-31)NH₂ reduced the blood pressure by only 11.1 ± 1.6 mm Hg when injected subcutaneously as compared with 51.6 ± 3.3 mm Hg when injected intravenously.

20 There was no significant difference between the rapid and large reductions in the tail artery pressure caused by intravenously injected hPTH-(1-84), hPTH-(1-34), and hPTH-(1-31)NH₂, but hPTH-(1-34), was at least twice as effective ($P<0.01$) as the other two molecules when injected subcutaneously.

25 One of the factors that affects the hypotensive action and osteogenecity of subcutaneously injected PTH or a PTH fragment is its ability to move without being inactivated from the injection site to its targets first in the vasculature and then into the bones. This ability is reflected in the time required for the tail artery pressure to fall to its minimum value after injection. 30 Shortening the PTH molecule C-terminally from 84 to 31 residues eliminated the ability to stimulate PLC without diminishing the ability to stimulate AC and

it decreased by nine times the amount of time required for the tail artery pressure to reach its minimum. Removing one more residue to make hPTH-(1-30)NH₂ dramatically increased the amount of time required for the blood pressure to fall to its minimum from 2.0 ± 0.31 minutes in the case of hPTH-5 (1-31)NH₂ to 13.8 ± 2.3 minutes. However, it is important to note that hPTH-(1-31)NH₂ took no longer to reduce the blood pressure than hPTH-(1-84).

The use in the present study of hPTH-(1-31)NH₂, the first PTH construct to be able to stimulate AC as strongly as hPTH-(1-34) without activating PLC and stimulating membrane-associated PKCs activity, has now 10 provided the most direct proof that PTH's hypotensive action is due entirely to AC activation. Thus, although intravenous injection of 0.8 nmol/100 g of body weight of hPTH-(7-84), which can only stimulate PLC/PKCs, did not significantly affect tail artery pressure, intravenous injection of the same dose of hPTH-(1-31)NH₂ dropped the pressure as much as hPTH-(1-34).

15 Since AC also mediates the PTH-induced stimulation of cortical and trabecular bone formation in OVX rats, the triggering of a hypotensive response in intact female rats appears to be a simple, rapidly measurable indicator of a PTH construct's possible osteogenicity. On the other hand, failure to reduce arterial pressure would eliminate a fragment from further 20 assessment, thus avoiding unnecessary, expensive, long-term osteogenicity test in OVX rats. The hypotensive responses to intravenous injection of the PTHs were not correlated to osteogenicities. However, the much smaller hypotensive responses to subcutaneously injected hPTH-(1-31)NH₂, hPTH-(1-34), and hPTH-(1-84) did parallel the osteogenicities of these molecules, 25 with hPTH-(1-34) having the strongest hypotensive and osteogenic actions and the other two molecules being as effective as each other, but less effective than hPTH-(1-34), in reducing the blood pressure and stimulating bone formation. But this correlation broke down with hPTH-(1-30)NH₂ which stimulates AC almost as strongly as hPTH-(1-31)NH₂ and hPTH-(1-34) and 30 reduced blood pressure as much as hPTH-(1-31)NH₂ but does not stimulate bone formation¹¹. The reason for this lack of osteogenicity is unknown. It

cannot be due only to subcutaneously injected hPTH-(1-30)NH₂ needing more time to reduce the blood pressure, because subcutaneously injected hPTH-(1-84) needs the same amount of time to reduce the blood pressure, yet is strongly osteogenic. Clearly the osteogenic response depends on

5 many different factors that combine to enable the arrival from the injection site of enough active hormone or hormone fragment at target PTH receptor-expressing mature osteoblasts. The failure of the AC-stimulating, blood pressure-reducing hPTH-(1-30)NH₂ to stimulate bone formation might be the result of a combination of greater instability, a slightly higher EC₅₀ for AC

10 stimulation i.e. 20nM instead of the 16 nM for hPTH-(1-31)NH₂ and hPTH-(1-34) and a long time to enter the circulation from the injection site.

Despite the failure of hPTH-(1-30)NH₂ to be osteogenic, the ability to significantly reduce arterial pressure is still a common property of the osteogenic PTHs and is therefore a rapidly determinable indicator of possible

15 *in vivo* bioactivity of PTH fragments. It follows that the hypotensive response should also serve as an effective indicator of the ability of an osteogenic PTH construct to reach its targets after administration by oral or other noninjectable routes.

The discomfort and other possible sequelae of a hypotensive reaction

20 to each injection might limit the willingness of osteoporotic patients to accept long-term treatment with PTH or a PTH fragment. Fortunately, intermittent subcutaneous injections of the PTHs are currently used to stimulate bone formation and these molecules are all far less hypotensive when injected subcutaneously than when injected intravenously. As we have also argued

25 previously ^{6,7}. hPTH-(1-31)NH₂ would have the added advantage of stimulating AC without stimulating PLC and any potential Ca²⁺ - and PKCs-mediated side-effects it might trigger.

Example 7

30 Cyclo(Lys²⁷-Asp³⁰)-hPTH-(1-31)-NH₂ (5). The synthesis was performed in an analogous manner to that of [Leu²⁷]-cyclo(Glu²²-Lys²⁶)-hPTH-(1-31)-NH₂. The product had an estimated purity of >95%, with a molecular mass of

3700.64 (± 0.38) (expected $M+1 = 3700.14$). The peptide was sequenced to confirm the lactam position.

[Leu²⁷]-cyclo(Glu²²-Lys²⁶)-hPTH-(1-30)-NH₂ (8). This peptide was

synthesized as for peptide 3, without manual addition of Val to the support.

5 The product had an estimated purity of >97%, with a molecular mass of 3586.14 (± 0.19) (expected $M+1 = 3685.99$).

The analogues of the present invention may be administered to a warm-blooded mammal, in need thereof, particularly a human, by parenteral, topical, or rectal administration, or by inhalation or by oral delivery.. The 10 analogues may be conventionally formulated in a parenteral dosage form compounding about 1 to about 300 mg per unit of dosage with a conventional vehicle, excipient, binder, preservative, stabilizer, color, agent or the like as called for by accepted pharmaceutical practice.

For parenteral administration, a 1 to 2 ml painless subcutaneous 15 injection through an ultra-fine 30-gauge syringe needle would need to be given no more than once daily, for one to 2 years, depending on the severity of the disease. The injected material would contain one of the present invention in an aqueous, isotonic, sterile solution or suspension (optionally with a preservative such as phenol or a solubilizing agent such as 20 ethylenediamine tetraacetic acid (EDTA)). Among the acceptable vehicles and solvents that may be employed are water, mildly acidified water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. Synthetic monoglycerides, diglycerides, fatty acids (such as oleic acid) find use as a 25 fixed oil in the preparation of injectables.

For rectal administration, the analogues of the present invention can be prepared in the form of suppositories by mixing with a suitable non-irritating excipient such as cocoa butter or polyethylene glycols.

For topical use, the analogues of the present invention can be prepared in the form of ointments, jellies, solutions, suspensions or dermal adhesive patches.

5 For inhalation, this can be achieved, for example, by means described in PCT published application no. W094/07514.

The daily dose should not have to exceed 0.05 mg/kg of body weight, or about 3.5 mg/ 70 kg human, depending on the activity of the specific compound, the age, weight, sex, and conditions of the subject being treated.

10 As would be well known, the amount of active ingredient that may be combined with the carried materials to produce a single dosage will vary depending upon the host treated and the particular mode of administration.

15 The following tabulated list of analogues were all produced in accordance with the procedures described above.

Table 1 Molecular Masses of PTH Analogues

SEQ ID	Analogue	Mass (determined)	Mass (expected) (M+1)
1	hPTH-(1-31)-NH ₂	3717.77 (±0.13)	3717.14
3	[Leu ²⁷]cyclo(Glu ²² -Lys ²⁶)-hPTH-(1-31)-NH ₂	3685.46 (±0.46)	3685.12
7	[Leu ²⁷]cyclo(Glu ²² -Lys ²⁶)-hPTH-(1-30)-NH ₂	3586.14 (±0.19)	3585.99
4	[Leu ²⁷]cyclo(Lys ²⁶ -Asp ³⁰)-hPTH-(1-31)-NH ₂	3685.61 (±0.36)	3685.12
6	cyclo(Lys ²⁷ -Asp ³⁰)-hPTH-(1-31)-NH ₂	3700.64 (±0.38)	3700.14
8	[Leu ²⁷]cyclo(Glu ²² -Lys ²⁶)-hPTH-(1-31)-OH	3685.96 (±0.07)	3686.12
9	[Leu ²⁷]cyclo(Glu ²² -Lys ²⁶)-hPTH-(1-34)-NH ₂	4083.62 (±0.33)	4083.52
10	[Leu ²⁷]cyclo(Glu ²² -Lys ²⁶)-hPTH-(1-34)-OH	4084.14 (±0.87)	4084.52
11	[Ala ²⁷]cyclo(Glu ²² -Lys ²⁶)-hPTH-(1-31)-NH ₂	3642.70 (±0.76)	3643.04
12	[Nle ²⁷]cyclo(Glu ²² -Lys ²⁶)-hPTH-(1-31)-NH ₂	3684.57 (±0.99)	3685.12
13	[Nle ^{8,18} ;Leu ²⁷]cyclo(Glu ²² -Lys ²⁶)-hPTH-(1-31)-NH ₂	3649.50 (0.59)	3649.04
14	cyclo(Glu ²² -Lys ²⁶)-hPTH-(1-31)-NH ₂	3699.66 (±0.49)	3700.14
15	[Ile ²⁷]cyclo(Glu ²² -Lys ²⁶)-hPTH-(1-31)-NH ₂	3684.76 (±0.74)	3685.12

Table 1 Molecular Masses of PTH Analogues

SEQ ID	Analogue	Mass (determined)	Mass (expected) (M+1)
16	[Tyr ²⁷]cyclo(Glu ²² -Lys ²⁶)-hPTH-(1-31)-NH ₂	3734.47 (±0.80)	3735.14
17	α-acetyl-[Leu ²⁷]cyclo(Glu ²² -Lys ²⁶)-hPTH-(1-31)-NH ₂	3726.25 (±0.42)	3727.12
18	[Leu ²⁷]cyclo(Lys ²² -Glu ²⁶)-hPTH-(1-31)-NH ₂	3684.67 (±0.52)	3685.12
19	[Leu ²⁷]cyclo(Asp ²² -Orn ²⁶)-hPTH-(1-31)-NH ₂	3656.90 (±0.67)	3657.12
20	[Cys ²² ;Cys ²⁶ ;Leu ²⁷]cyclo(Cys ²² -Cys ²⁶)hPTH(1-31)NH ₂	3651.26 ±0.31	3650.1
21	[Cys ²⁶ ;Cys ³⁰ ;Leu ²⁷]cyclo(Cys ²⁶ -Cys ³⁰)hPTH(1-31)NH ₂	3663.61 ±0.16	3664.13

Table 2 Adenylyl Cyclase (AC) Activities of Peptide Analogues

SEQ ID	Analogue	Adenylyl Cyclase (EC ₅₀)
1	hPTH-(1-31)-NH ₂	20
3	[Leu ²⁷]cyclo(Glu ²² -Lys ²⁶)-hPTH-(1-31)-NH ₂	3
7	[Leu ²⁷]cyclo(Glu ²² -Lys ²⁶)-hPTH-(1-30)-NH ₂	20
4	[Leu ²⁷]cyclo(Lys ²⁶ -Asp ³⁰)-hPTH-(1-31)-NH ₂	3*,17**
6	cyclo(Lys ²⁷ -Asp ³⁰)-hPTH-(1-31)-NH ₂	40
8	[Leu ²⁷]cyclo(Glu ²² -Lys ²⁶)-hPTH-(1-31)-OH	7
9	[Leu ²⁷]cyclo(Glu ²² -Lys ²⁶)-hPTH-(1-34)-NH ₂	8
10	[Leu ²⁷]cyclo(Glu ²² -Lys ²⁶)-hPTH-(1-34)-OH	6
11	[Ala ²⁷]cyclo(Glu ²² -Lys ²⁶)-hPTH-(1-31)-NH ₂	9
12	[Nle ²⁷]cyclo(Glu ²² -Lys ²⁶)-hPTH-(1-31)-NH ₂	9
13	[Nle ^{8,18} ,Leu ²⁷]cyclo(Glu ²² -Lys ²⁶)-hPTH-(1-31)-NH ₂	6
14	cyclo(Glu ²² -Lys ²⁶)-hPTH-(1-31)-NH ₂	17
15	[Ile ²⁷]cyclo(Glu ²² -Lys ²⁶)-hPTH-(1-31)-NH ₂	9

Table 2 Adenylyl Cyclase (AC) Activities of Peptide Analogues

SEQ ID	Analogue	Adenylyl Cyclase (EC ₅₀)
16	[Tyr ²⁷]cyclo(Glu ²² -Lys ²⁶)-hPTH-(1-31)-NH ₂	9
17	α -acetyl-[Leu ²⁷]cyclo(Glu ²² -Lys ²⁶)-hPTH-(1-31)-NH ₂	24
18	[Leu ²⁷]cyclo(Lys ²² -Glu ²⁶)-hPTH-(1-31)-NH ₂	4
19	[Leu ²⁷]cyclo(Asp ²² -Orn ²⁶)-hPTH-(1-31)-NH ₂	>200
20	[Cys ²² ,Cys ²⁶ ,Leu ²⁷]cyclo(Cys ²² -Cys ²⁶)hPTH(1-31)NH ₂	16
21	[Cys ²⁶ ,Cys ³⁰ ,Leu ²⁷]cyclo(Cys ²⁶ -Cys ³⁰)hPTH(1-31)NH ₂	24

* Fig. 4
** Fig. 12

REFERENCES

The disclosures of the following references are incorporate herein by reference.

5

(1) Caulfield, M. P.; McKee, R. L.; Goldman, M. E.; Duong, L. T.; Fisher, J. E.; Gay, C. T.; DeHaven, P. A.; Levy, J. J.; Roubini, E.; Nutt, R. F.; Chorev, M.; Rosenblatt, M. The Bovine Renal Parathyroid Hormone(PTH) Receptor Has Equal Affinity for 2 Different Amino Acid Sequences - The Receptor

10 Binding Domains of PTH and PTH-Related Protein Are Located Within the 14-34 Region. *Endocrinology* **1990**, *127*, 83-87.

(2) Neugebauer, W.; Barbier, J.-R.; Sung, W.L.; Whitfield, J.F.; Willick, G.E. Solution Structure and Adenylyl Cyclase Stimulating Activities of C-Terminal

15 Truncated Human Parathyroid Hormone Analogues *Biochemistry* **1995**, *34*, 8835-8842.

(3) Gardella, T. J.; Wilson, A. K.; Keutmann, H. T.; Oberstein, R.; Potts, J. T.; Kronenberg, H.M., and Nussbaum, S. R. Analysis of Parathyroid

20 Hormone's Principal Receptor-Binding Region by Site-Directed Mutagenesis and Analog Design. *Endocrinology* **1993**, *132*, 2024-2030.

(4) Marqusee, S.; Baldwin, R.L. Helix Stabilization by Glu ...Lys+ Salt Bridges in Short Peptides of *De Novo* Design. *Proc. Natl. Acad. Sci. U.S.A.*

25 **1987**, *84*, 8898-8902.

(5) Surewicz, W.K.; Neugebauer, W.; Gagnon, L.; MacLean, S.; Whitfield, J.F.; Willick, G.E. Structure-Function Relationships in Human Parathyroid Hormone: The Essential Role of Amphiphilic-Helix. In *Peptides: Chemistry, Structure, and Biology* 1993; Smith, J.; Hodges, R., Eds.; ESCOM Leiden, 5 The Netherlands, 1993, pp. 556-558

(6) Whitfield, J. F.; Morley, P.; Willick, G. E.; Ross, V.; Barbier, J. R.; Isaacs, R. J.; Ohannessianbarry, L. Stimulation of the Growth of Femoral Trabecular Bone in Ovariectomized Rats by the Novel Parathyroid Hormone 10 Fragment, hPTH-(1-31)NH₂ (Ostabinol) *Calcif. Tissue Int.* **1996**, 58, 81-87.

(7) Whitfield, J. F.; Morley, P. Small Bone-Building Fragments of Parathyroid Hormone: New Therapeutic Agents for Osteoporosis *Trends Pharmacol. Sci.* **1995** 16, 382-386.

15

SEQUENCE LISTING

(1) GENERAL INFORMATION:

5

(i) APPLICANT:

(A) NAME: National Research Council of Canada
(B) STREET: Intellectual Property Services
Montreal Road, Bldg. M-58, Room EG-12
10 (C) CITY: Ottawa
(D) STATE: Ontario
(E) COUNTRY: Canada
(F) ZIP: K1A 0R6

15

(ii) TITLE OF INVENTION: PARATHYROID HORMONE ANALOGUES FOR THE
TREATMENT OF OSTEOPOROSIS

(iii) NUMBER OF SEQUENCES: 33

20

(iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30

25

(v) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: PCT/CA97/00547
(B) FILING DATE: 01-AUG-1997

30

(vi) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: 08/691,647
(B) FILING DATE: 02-AUG-1996

35

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 31 amino acids
(B) TYPE: amino acid
40 (C) STRANDEDNESS:
(D) TOPOLOGY: linear

40

(ii) MOLECULE TYPE: protein

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

50

Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1 5 10 15

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val
20 25 30

5 (2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 31 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

614 MOLECULE-TYPE *insectiv.*

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

20 Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1 5 10 15

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Leu Leu Gln Asp Val
 20 25 30

25 (2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 31 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: circular

35 (ii) MOLECULE TYPE: protein

(a) SURVEY REGISTRATION, SHEET NO. 2

40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1 5 10 15

45 Ser Met Glu Arg Val Glu Trp Leu Arg Lys Leu Leu Gln Asp Val
20 25 30

(2) INFORMATION FOR SEQ ID NO:4:

5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: circular

10 (ii) MOLECULE TYPE: protein

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1 5 10 15
Ser Met Glu Arg Val Glu Trp Leu Arg Lys Leu Leu Gln Asp Val
20 25 30

(2) INFORMATION FOR SEQ ID NO:5:

25 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: protein

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1 5 10 15
Ser Met Glu Arg Val Glu Trp Leu Arg Lys Leu Leu Gln Asp Val
40 20 25 30

45 (2) INFORMATION FOR SEQ ID NO:6:

50 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: protein

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

10	Ser	Val	Ser	Glu	Ile	Gln	Leu	Met	His	Asn	Leu	Gly	Lys	His	Leu	Asn
	1				5					10					15	
	Ser	Met	Glu	Arg	Val	Glu	Trp	Leu	Arg	Lys	Lys	Leu	Gln	Asp	Val	
					20				25					30		

15

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: protein

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

35

(2) INFORMATION FOR SEQ ID NO:8:

40

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

5	Ser	Val	Ser	Glu	Ile	Gln	Leu	Met	His	Asn	Leu	Gly	Lys	His	Leu	Asn
	1				5					10					15	
	Ser Met Glu Arg Val Glu Trp Leu Arg Lys Leu Leu Gln Asp Val															
					20					25				30		

10 (2) INFORMATION FOR SEQ ID NO:9:

15 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 34 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: circular

20 (ii) MOLECULE TYPE: protein

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:
Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1 5 10 15
30 Ser Met Glu Arg Val Glu Trp Leu Arg Lys Leu Leu Gln Asp Val His
20 25 30
Asn Phe

35 (2) INFORMATION FOR SEQ ID NO:10:

40 (i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 34 amino ac
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: circular

45 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1 5 10 15

5 Ser Met Glu Arg Val Glu Trp Leu Arg Lys Leu Leu Gln Asp Val His
 20 25 30

 Asn Phe

10 (2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 31 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: circular

20 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

30 Ser Met Glu Arg Val Glu Trp Leu Arg Lys Ala Leu Gln Asp Val
20 25 30

(2) INFORMATION FOR SEQ ID NO:12:

35 (i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 31 amino ac
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: circular

40 (ii) MOLECULE TYPE: protein

45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

1 Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
 5 10 15

50 Ser Met Glu Arg Val Glu Trp Leu Arg Lys Xaa Leu Gln Asp Val
20 25 30

(2) INFORMATION FOR SEQ ID NO:13:

5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: circular

10 (ii) MOLECULE TYPE: peptide

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Ser Val Ser Glu Ile Gln Leu Xaa His Asn Leu Gly Lys His Leu Asn
1 5 10 15

20 Ser Xaa Glu Arg Val Glu Trp Leu Arg Lys Leu Leu Gln Asp Val
20 25 30

(2) INFORMATION FOR SEQ ID NO:14:

25 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: circular

30 (ii) MOLECULE TYPE: protein

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1 5 10 15

40 Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val
20 25 30

(2) INFORMATION FOR SEQ ID NO:15:

5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: circular

10 (ii) MOLECULE TYPE: protein

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

15 Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1 5 10 15
20 Ser Met Glu Arg Val Glu Trp Leu Arg Lys Ile Leu Gln Asp Val
20 25 30

(2) INFORMATION FOR SEQ ID NO:16:

25 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: circular

30 (ii) MOLECULE TYPE: protein

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

35 Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1 5 10 15
40 Ser Met Glu Arg Val Glu Trp Leu Arg Lys Tyr Leu Gln Asp Val
20 25 30

(2) INFORMATION FOR SEQ ID NO:17:

45 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: circular

50 (ii) MOLECULE TYPE: protein

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1 5 10 15

10 Ser Met Glu Arg Val Glu Trp Leu Arg Lys Leu Leu Gln Asp Val
20 25 30

(2) INFORMATION FOR SEQ ID NO:18:

15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: protein

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1 5 10 15

30 Ser Met Glu Arg Val Lys Trp Leu Arg Glu Leu Leu Gln Asp Val
20 25 30

(2) INFORMATION FOR SEQ ID NO:19:

35 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: circular

40 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

5 Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1 5 10 15

10 Ser Met Glu Arg Val Asp Trp Leu Arg Xaa Leu Leu Gln Asp Val
20 25 30

10 (2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:
15 (A) LENGTH: 31 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: circular

20 (ii) MOLECULE TYPE: protein

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

25 Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1 5 10 15

30 Ser Met Glu Arg Val Cys Trp Leu Arg Cys Leu Leu Gln Asp Val
20 25 30

30 (2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:
35 (A) LENGTH: 31 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: circular

40 (ii) MOLECULE TYPE: protein

45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

45 Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1 5 10 15

50 Ser Met Glu Arg Val Glu Trp Leu Arg Cys Leu Leu Gln Cys Val
20 25 30

(2) INFORMATION FOR SEQ ID NO:22:

5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1 5 10 15

20 Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

25 (2) INFORMATION FOR SEQ ID NO:23:

30 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

35 (ii) MOLECULE TYPE: protein

40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

Xaa Val Ser Glu Ile Gln Leu Xaa His Asn Leu Gly Lys Xaa Xaa Xaa
1 5 10 15

45 Xaa Xaa Glu Arg Val Xaa Trp Leu Xaa Xaa Xaa Leu Xaa Asp Xaa
20 25 30

(2) INFORMATION FOR SEQ ID NO:24:

50 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4 amino acids
(B) TYPE: amino acid

(C) STRANDEDNESS:
(D) TOPOLOGY: linear

5 (ii) MOLECULE TYPE: peptide

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

Val His Asn Xaa
1

15 (2) INFORMATION FOR SEQ ID NO:25:

15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
20 (D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: peptide

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

30 Val His Asn Phe Xaa
1 5

35 (2) INFORMATION FOR SEQ ID NO:26:

35 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

40 (ii) MOLECULE TYPE: peptide

45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

50

5
Val His Asn Phe Val Xaa
1 5

10 (2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:
10 (A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: peptide

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

Val His Asn Phe Val Ala Xaa
1 5

25 (2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:
25 (A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

40 Val His Asn Phe Val Ala Leu Xaa
1 5

45 (2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:
45 (A) LENGTH: 4 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

50

5 (ii) MOLECULE TYPE: peptide

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

His Lys Lys Lys
1

15 (2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4 amino acids
(B) TYPE: amino acid
20 (C) STRANDEDNESS:
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

His Leu Lys Lys
1

30 (2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4 amino acids
(B) TYPE: amino acid
35 (C) STRANDEDNESS:
(D) TOPOLOGY: linear

40 (ii) MOLECULE TYPE: peptide

45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

Lys Lys Lys Lys
1

50 (2) INFORMATION FOR SEQ ID NO:32:

5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

15 His Leu Lys Ser
1

(2) INFORMATION FOR SEQ ID NO:33:

20 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

30 Val Leu Asn Phe Xaa
1 5

CLAIMS:

1. A human parathyroid hormone hPTH-(1-31)analogue in which position 27 is Lys or has been substituted by a suitable hydrophobic residue, and which 5 has been cyclized to form a lactam.
2. An analogue according to Claim 1, wherein the cyclisation is either as between Glu²² and Lys²⁶ or as between Lys²⁶ and Asp³⁰.
- 10 3. An analogue according to Claim 1, wherein the hydrophobic residue is Leu.
4. An analogue according to Claim 1, wherein the hydrophobic residue is selected from the group consisting of ornithine, citrulline, α -aminobutyric acid, or any linear or branched α -amino aliphatic acid, having 2-10 carbons in the 15 side chain, any such analogue having a polar or charged group at the terminus of the aliphatic chain.
5. An analogue according to Claim 4, wherein the hydrophobic residue is selected from the group consisting of Ile, norleucine, Met, and ornithine.
- 20 6. An analogue according to Claim 1, having either a C-terminal amide ending or a C-terminal carboxyl ending.
7. An analogue according to Claim 1, having the SEQ ID NO: 3.
- 25 8. An analogue according to Claim 1, having the SEQ ID NO: 4.
9. A composition for administration to a warm-blooded animal in need thereof, comprising a human parathyroid hormone (hPTH)-(1-31) analogue 30 according to Claim 1, in association with a pharmaceutically acceptable carrier or excipient.

10. A composition according to Claim 9, wherein the analogue the hydrophobic residue is Leu.

11. A composition according to Claim 9, wherein the analogue the 5 hydrophobic residue is selected from the group consisting of Ile, norleucine, Met, and ornithine.

12. A composition according to Claim 9, the analogue having the SEQ ID NO: 3.

10

13. A composition according to Claim 9, the analogue having the SEQ ID NO: 4.

15

14. A method of treating a warm-blooded animal in need of such treatment, comprising administering to such warm-blooded animal, a therapeutically effective amount of a human parathyroid hormone (hPTH)-(1-31) analogue according to Claim 1.

20

15. A method according to Claim 14, wherein the analogue the hydrophobic residue is Leu.

16. A method according to Claim 14, wherein the analogue the hydrophobic residue is selected from the group selected from the group consisting of Ile, norleucine, Met, and ornithine.

25

17. A method according to Claim 14, the analogue having the SEQ ID NO: 3.

18. A method according to Claim 15, the analogue having the SEQ ID NO: 4.

30

19. A human parathyroid hormone hPTH and pharmaceutically acceptable salts thereof, having the amino acid sequence

R-NH-R1-Val-Ser-Glu-Ile-Gln-Leu-R2-His-Asn-Leu-Gly-Lys-R3-R4-R5-R6-R7-Glu-Arg-Val-R8--Trp-Leu-R9--R10--R11-Leu-R12-Asp--Y

wherein,

5

R = hydrogen or any linear or branched chain alkyl, acyl or aryl group,

R1 = Ser, Ala or Aib,

R2 = Met, or a naturally occurring hydrophobic amino acid,

R3 = His or a water soluble amino acid,

10 R4 = Leu or a water soluble amino acid,

R5 = Asn or a water soluble amino acid,

R6 = Ser or a water soluble amino acid,

R7 = Met, or a naturally occurring hydrophobic amino acid,

R8 = Glu, Lys or Asp,

15 R9 = Cys, Glu or Orn,

R10 = Arg, Lys, Orn, Gln, Glu or Asp

R11 = a naturally occurring hydrophobic or polar amino acid,

R12 = Gln, Arg, Glu, Asp, Lys or Orn,

X = OH, NH₂, and

20 Y = X, Val-X, Val-His-X, Val-His-Asn-X, Val-His-Asn-Phe-X, Val-His-Asn-Phe-Val-X, Val-His-Asn-Phe-Val-Ala-X and Val-His-Asn-Phe-Val-Ala-Leu-X, cyclized as between one or two amino acid pairs 22 and 26, 26 and 30, 27 and 30, and 25 and 29 when R3 and R6 are Lys, Orn, Glu or Asp, excluding cyclo(Lys²⁶-Asp³⁰)[Leu²⁷]-hPTH-(1-34)-NH₂, cyclo(Lys²⁷-Asp³⁰)-h-PTH-(1-34)-NH₂ and cyclo(Lys²⁶-Asp³⁰)-[Leu²⁷]-hPTH-(1-34)-OH.

20. An analogue according to Claim 19, wherein the cyclisation is in the form of a lactam.

21. An analogue according to Claim 20, wherein the lactam is an i, i+4 lactam.
22. An analogue according to Claim 21, wherein the lactam is a Glu22-5 Lys26 lactam.
23. An analogue according to Claim 21, wherein the lactam is Lys26-Asp30 lactam.
- 10 24. An analogue according to Claim 20, wherein R is H and X is NH₂.
25. An analogue according to Claim 24, wherein R11 is Lys or Leu.
- 15 26. An analogue according to Claim 25, wherein R2 and R7 are Met or Nle.
27. An analogue according to Claim 26, wherein R1 is Ser, R2 is Met, R7 is Met, R8 is Glu, R9 is Arg, R10 is Lys and R12 is Gln .
- 20 28. An analogue according to Claim 27, wherein R3 is His or Lys, R4 is Leu, Lys or Arg, R5 is Asn, Orn, Hci, Asp, Arg, Lys, D-Lys, Ser or Gly, and R6 is Ser, Lys, Asp or Arg.
- 25 29. An analogue according to Claim 27, wherein R3-R6 is His-Lys-Lys-Lys, His- Leu- Lys-Lys, Lys-Lys-Lys-Lys or His-Leu-Lys-Ser.
- 30 30. An analogue according to Claim 27, wherein Y = X.
31. An analogue according to Claim 27, wherein Y = Val-X.

32. An analogue according to Claim 27, wherein Y = Val-Leu-Asn-Phe-X.
33. An analogue according to Claim 19, having the SEQ ID NO: 6.
- 5 34. An analogue according to Claim 19, having the SEQ ID NO: 7.
35. An analogue according to Claim 19, having the SEQ ID NO: 8.
- 10 36. An analogue according to Claim 19, having the SEQ ID NO: 9.
37. An analogue according to Claim 19, having the SEQ ID NO: 10.
38. An analogue according to Claim 19, having the SEQ ID NO: 11.
- 15 39. An analogue according to Claim 19, having the SEQ ID NO: 12.
40. An analogue according to Claim 19, having the SEQ ID NO: 13.
- 20 41. An analogue according to Claim 19, having the SEQ ID NO: 14.
42. An analogue according to Claim 19, having the SEQ ID NO: 15.
43. An analogue according to Claim 19, having the SEQ ID NO: 16.
- 25 44. An analogue according to Claim 19, having the SEQ ID NO: 17.
45. An analogue according to Claim 19, having the SEQ ID NO: 18.
- 30 46. An analogue according to Claim 19, having the SEQ ID NO: 19.

47. A method for screening peptide constructs for osteogenicity, comprising

- (a) anesthetizing a test animal,
- 5 (b) subcutaneously injecting the test animal with an effective dosage of a candidate peptide or a pharmaceutically acceptable salt thereof, dissolved in a pharmaceutically acceptable solvent, and
- (c) measuring the arterial blood pressure of the animal, whereby a small blood pressure drop after a short time period, is indicative of
10 osteogenicity of the peptide.

48. A method according to Claim 47, wherein the solvent is acidified saline.

15 49. A method according to Claim 48, wherein the solvent includes .0001 N HCl.

50. A method according to Claim 49, wherein the test animal is a rat, and the blood pressure drop is 8.5 to 36.2%, at 2 to 19 minutes post
20 injection.

51. A method according to Claim 50, wherein the peptide is an hPTH fragment according to Claim 19.

25 52. A method according to Claim 51, wherein the dosage of hPTH is about 0.8 nmole/110 g of body weight.

53. A method according to Claim 52, wherein the hPTH is of SEQ ID NO: 3.

54. A method according to Claim 52, wherein the hPTH is of SEQ ID NO: 4.

H₂N-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-COOH

Fig. 1

H₂N-Ser-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-
Val-Glu-Trp-Leu-Arg-Lys-Leu-Leu-Gln-Asp-Val-NH₂

Fig. 2

H₂N-Ser-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-
Val-Glu-Trp-Leu-Arg-Lys-Leu-Leu-Gln-Asp-Val-NH₂

Fig. 3

2/15




Fig. 4

3/15




Fig. 5

4/15




Fig. 6

5/15




Fig. 7

6/15




Fig. 8

7/15

H₂N-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Leu-Leu-Gln-Asp-Val-NH₂

Fig. 9

H₂N-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-
Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-NH₂

Fig. 10

H₂N-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-
Val-Glu-Trp-Leu-Arg-Lys-Leu-Gln-Asp-NH₂

Fig. 11

8/15




Fig. 12

9/15





Fig. 13



10/15







Fig. 14




11/15

**Fig. 15****Fig. 16****Fig. 17**

12/15

$$\text{H}_2\text{N-Ser-Val-Ser-Glu-ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-}$$
$$\overbrace{\text{Glu-Trp-Leu-Arg-Lys-Ala-Leu-Gln-Asp-Val-NH}_2}$$
Fig. 18
$$\text{H}_2\text{N-Ser-Val-Ser-Glu-ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-}$$
$$\overbrace{\text{Val-Glu-Trp-Leu-Arg-Lys-Nle-Leu-Gln-Asp-Val-NH}_2}$$
Fig. 19
$$\text{H}_2\text{N-Ser-Val-Ser-Glu-ile-Gln-Leu-Nle-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Nle-Glu-Arg-}$$
$$\overbrace{\text{Val-Glu-Trp-Leu-Arg-Lys-Leu-Leu-Gln-Asp-NH}_2}$$
Fig. 20

13/15

**Fig. 21****Fig. 22****Fig. 23**

14/15

CH₃COHN-Ser-Val-Ser-Glu-ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-

Glu-Trp-Leu-Arg-Lys-Leu-Leu-Gln-Asp-Val-NH₂

Fig. 24

H₂N-Ser-Val-Ser-Glu-ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-

Val-Lys-Trp-Leu-Arg-Glu-Leu-Leu-Gln-Asp-Val-NH₂

Fig. 25

H₂N-Ser-Val-Ser-Glu-ile-Gln-Leu-Nle-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Nle-Glu-Arg-

Val-Asp-Trp-Leu-Arg-Gln-Leu-Gln-Asp-Val-NH₂

Fig. 26

15/15

H₂N-Ser-Val-Ser-Glu-ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-

Cys-Trp-Leu-Arg-Cys-Leu-Leu-Gln-Asp-Val-NH₂

Fig. 27

H₂N-Ser-Val-Ser-Glu-ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-

Val-Lys-Trp-Leu-Arg-Cys-Leu-Leu-Gln-Cys-Val-NH₂

Fig. 28

INTERNATIONAL SEARCH REPORT

Intern	nal Application No
PCT/CA 97/00547	

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07K14/635

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CA 2 126 299 A (WILLICK GORDON E ;WHITFIELD JAMES F (CA); SUREWICZ WITOLD (CA); SU) 21 December 1995 see the whole document see claims 1-3; figures 1-10; table 1	1-18
Y	---	19-46, 51-54
X	WO 93 06845 A (PANG PETER K T) 15 April 1993 cited in the application see abstract; claims 1-10 see example 1	47-50
Y	---	1-46, 51-54
		-/-



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "Z" document member of the same patent family

2

Date of the actual completion of the international search

9 December 1997

Date of mailing of the international search report

09.01.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Cervigni, S

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 97/00547

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	T. KANMERA ET AL.: "Conformationally constrained PTH-related protein antagonists" PEPTIDES. PROCEEDINGS OF THE 23TH EUROPEAN PEPTIDE SYMPOSIUM, 1994, pages 650-651, XP002049214 see table 1 ---	1-46
Y	NEUGEBAUER W ET AL: "STRUCTURE AND PROTEIN KINASE C STIMULATING ACTIVITIES OF LACTAM ANALOGUES OF HUMAN PARATHYROID HORMONE FRAGMENT" INTERNATIONAL JOURNAL OF PEPTIDE AND PROTEIN RESEARCH, vol. 43, no. 6, 1 June 1994, pages 555-562, XP000442516 see page 558, paragraph 1	1-46
Y	CHOREV M ET AL: "CYCLIC PARATHYROID HORMONE RELATED PROTEIN ANTAGONISTS: LYSINE 13 TO ASPARTIC ACID 17 (I TO (I + 4)) SIDE CHAIN TO SIDE CHAIN LACTAMIZATION" BIOCHEMISTRY, vol. 30, no. 24, 18 June 1991, pages 5968-5974, XP000206326 see the whole document	1-46
Y	GB 2 269 176 A (SANDOZ LTD) 2 February 1994 see claim 1 see the whole document	1-46
Y	W.K. SUREWICZ: "Structure-function relationship in hPTH" PEPTIDES: CHEMISTRY, STRUCTURE AND BIOLOGY - PROCEEDINGS OF THE 13TH AMERICAN PEPTIDE SYMPOSIUM, 1993, XP002049215 see page 558, paragraph 2; table 1	1-46
Y	WO 95 11988 A (AFFYMAX TECH NV ;OLDENBURG KEVIN R (US); SELICK HAROLD E (US)) 4 May 1995 see the whole document	1-46

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA 97/00547

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Remark : Although claims 47-54 are directed at least in part to a diagnostic method practised on the human/animal body and claims 14-16 are directed to a method of treatment of the human/animal body , the search has been carried out and based on the alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat'l Application No
PCT/CA 97/00547

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
CA 2126299 A	21-12-95	US 5556940 A	17-09-96

WO 9306845 A	15-04-93	US 5317010 A	31-05-94
		AU 665587 B	11-01-96
		AU 2871292 A	03-05-93
		CA 2120946 A	15-04-93
		EP 0607325 A	27-07-94
		JP 7502024 T	02-03-95

GB 2269176 A	02-02-94	AU 4156693 A	20-01-94
		CA 2100423 A	16-01-94
		CH 688195 A	13-06-97
		CN 1099801 A	08-03-95
		CZ 9500088 A	18-10-95
		DE 4393381 T	27-04-95
		WO 9402510 A	03-02-94
		EP 0672057 A	20-09-95
		FI 950171 A	13-03-95
		HU 70459 A	30-10-95
		HU 9500320 A	30-10-95
		IL 106326 A	30-09-97
		JP 6184198 A	05-07-94
		MX 9304251 A	28-02-94
		NO 950123 A	15-03-95
		NZ 248137 A	21-12-95
		SK 4395 A	07-06-95
		ZA 9305126 A	16-01-95

WO 9511988 A	04-05-95	AU 8124594 A	22-05-95
		EP 0730661 A	11-09-96
		JP 9504177 T	28-04-97
